Biogen Inc. and Evotec SE: SG&A Spending Patterns Compared

Biogen Inc. vs. Evotec SE: A Decade of SG&A Spending Trends

In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, Biogen Inc. and Evotec SE have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses. Biogen's SG&A expenses have consistently been over 30 times higher than Evotec's, reflecting its expansive operational scale. From 2014 to 2023, Biogen's spending peaked in 2021, with a 38% increase from its 2016 low. Meanwhile, Evotec's SG&A expenses grew nearly tenfold, highlighting its aggressive expansion strategy. This divergence underscores Biogen's focus on maintaining its market position, while Evotec is rapidly scaling its operations. As the pharmaceutical landscape continues to shift, these spending patterns offer insights into each company's strategic priorities and market positioning.